DHR International Places Chief Executive Officer at Semafore Pharmaceuticals, Inc.

DHR INTERNATIONAL PLACES CHIEF EXECUTIVE OFFICER AT SEMAFORE PHARMACEUTICALS, INC. INDIANAPOLIS, IN – August 2007 – DHR International is pleased to announce the placement of Edward L. Jacobs as Chief Executive Officer of Semafore Pharmaceuticals, Inc. The search was led by John Baker, Executive Vice President and Global Life Sciences Practice Leader. Mr. Jacobs most recently was the Chief Operating Officer of SuperGen, Inc., a cancer drug developer, where he played a major role in helping manage the company’s growth by directing all business and commercial operations. Previously Mr. Jacobs was with ETEX Corporation as the President and Chief Executive Officer, which he successfully restructured and sold to Medtronic Corporation. Prior to joining ETEX Corporation, Mr. Jacobs held the title of Senior Vice President of Commercial Operations of Sequus, a drug delivery firm. Before Sequus, Mr. Jacobs was Founder and Chief Executive Officer of Trilex, a cancer vaccine innovator. Earlier in his career, he held sales and marketing positions of increasing responsibility at Syncor International, now Cardinal Health, Adria Labs, now Pfizer Oncology, and Johnson and Johnson. Semafore Pharmaceuticals, Inc. is a clinical stage drug discovery and development company focused on small molecule modulators of the PI3 Kinase and PTEN cell signaling pathway, a promising target pathway for multiple disorders, including the company’s focus –cancer. Semafore is one of the first biopharmaceutical companies to focus on both PI3K and PTEN and has successfully discovered and is developing a portfolio of drug candidates addressing these targets. For nearly 20 years DHR International has been a leading, privately held provider of executive search solutions with more than 40 wholly-owned offices spanning the globe. DHR’s renowned consultants specialize in all industries and functions in order to provide unparalleled senior-level executive search, management assessment and succession planning services tailored to the unique qualities and specifications of our select client base. For more information on DHR International, visit http://www.dhrinternational.com #####

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.